Financial Data and Key Metrics Changes - Cash, cash equivalents, and investments totaled $48.4 million for the quarter ended March 31, 2023, down from $59.2 million at the end of 2022, reflecting funding operations during the first quarter [24] - The company's net loss was $13.2 million or $0.45 loss per share for the quarter ended March 31, 2023, compared to a net loss of $5.1 million or $0.07 loss per share for the same quarter in 2022 [44] - Research and development expenses were $13.4 million for the quarter ended March 31, 2023, down from $14.1 million for the same quarter in 2022, primarily due to lower clinical costs [66] Business Line Data and Key Metrics Changes - The ongoing Phase 1 study for PRS-220 is on track, with top-line data expected in the second half of the year [47] - The Elarekibep Phase 2a study in asthma is a top priority, with AstraZeneca committed to additional resources and expanding the clinical footprint [31][12] - PRS-400 is advancing towards clinical development candidate nomination later this year, supported by preclinical data showing its potential [60] Market Data and Key Metrics Changes - The asthma therapeutics market is currently valued in the multibillion-dollar range, with Elarekibep targeting this significant opportunity [33] - The company anticipates a meaningful uptick in patient enrollment for the Elarekibep study due to protocol amendments and expanded clinical sites [14] Company Strategy and Development Direction - The company is focused on advancing its inhaled biologics pipeline for respiratory diseases, with a strategic emphasis on PRS-220 and PRS-400 [29] - The company is considering various transactions, including a potential spinout of its immune-oncology programs, to facilitate ongoing development [62] - The company aims to leverage anticipated modest milestones from existing collaborations while assessing opportunities in the equities market [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash reach objectives through appropriate investment decisions and partnerships [25] - The company remains committed to its respiratory franchise and is prepared to gate future investments based on the outcomes of ongoing studies [42] - Management highlighted the importance of the upcoming data readouts, particularly for the pamrevlumab program, which could significantly impact the company's strategy [71] Other Important Information - The company reported an increase in interest income to approximately $400,000 for the quarter ended March 31, 2023, due to rising interest rates [26] - The first quarter is typically a higher cash-burning quarter due to annual bonuses and insurance payments, but the operating cash burn decreased by more than $8 million compared to the first quarter of 2022 [65] Q&A Session Summary Question: What is the path forward for the PRS-220 program if FibroGen's Phase 3 looks good? - Management indicated that the ongoing Phase 1 is budgeted and on plan, with top-line data expected by the end of the year. Positive results from pamrevlumab could lead to a strong inflection point for PRS-220 [47][49] Question: What will be considered if the pamrevlumab trial fails? - Management stated that understanding the reasons for missing the endpoint is crucial. They believe that targeting the lung directly with an inhaled Anticalin will achieve better results [79][80] Question: What is the timeline for strategic decisions regarding the PRS-343 program? - Management noted that while no specific discussions could be disclosed, there is real interest in the program, and they expect to provide updates towards the back half of 2023 [75][76]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada EIN 30-0784346 (S ...

12 31 moderate asthmatics controlled on standard-of-care therapy (medium dose ICS with LABA) were dosed twice daily over four weeks randomized across two dose levels and placebo (1:1:1) Safety review performed of the following (compared to placebo): Changes in laboratory markers (immune biomarkers, clinical chemistry, and hematology) Pharmacokinetics Potential Large Market Opportunity in Moderate-to-Severe Asthma not Addressed by ICS/LABA before Injectable Biologics 3 5 INTERMITTENT AND MILD MILD-TO-MODERAT ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer Mary Fitzgerald - Vice President, Project Leader Elarekibep Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Rob Andrew - William Blair & Company Operator Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Confe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State o ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Chief Development Officer Conference Call Participants Jonathan Miller - Evercore ISI Matthew Phipps - William Blair & Company Jiale Song - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions]. At thi ...

PIERIS PHARMACEUTICALS CORPORATE PRESENTATION November 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, whether PRS-220 will ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Tom Bures - Chief Financial Officer Steve Yoder - President and Chief Executive Officer Hitto Kaufmann - Chief Scientific Officer Shane Olwill - Chief Development Officer Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Matt Phipps - William Blair Operator Good morning, ladies and gentlemen, and welcome to the Pieris Pharmaceuticals Second Quarter Earnin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other juri ...

PIERIS PHARMACEUTICALS CORPORATE PRESENTATION May 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing for initiation ...